CLOs on the Move

Finesse

www.finesse.com

 
California-based Finesse Solutions brings Silicon Valley technology to bioprocessing. Better performance, integrated intelligence, and plug-and-play bioprocess flexibility are provided by Finesse SmartParts™. Our TruFluor® single-use sensors are unparalleled in the industry. Our G3 Universal™ controllers enable sophisticated cell culture or fermentation recipes to run on any size or brand of vessel. Our TruBio® software provides an easy-to-use interface for upstream bioprocessing that can harmonize old and new equipment, aggregate in-line and off-line data, and electronically facilitate global technology transfer. Finesse enables you to supercharge your R&D laboratory or scale-up to a cGMP SmartFactory with equal ease: we offer complete services, including commissioning and validation.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.finesse.com
  • 3501 Leonard Ct
    Santa Clara, CA USA 95054
  • Phone: 408.570.9000

Executives

Name Title Contact Details

Similar Companies

EMR Experts

EMR Experts, Inc is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MediConnect Global

MediConnect Global is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

ChemoMetec

ChemoMetec is a worldwide leading manufacturer of automated cell counters and analysis equipment. We work closely with life science companies, research institutes, universities, hospitals, specialist clinics, and a wide range of food and beverage manuf...

New York County Health Services

New York County Health Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Plasmatech Biopharmaceuticals

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona’s lead program is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians. Clinical trials for Sanfilippo types A and B are anticipated to begin in 2015.